The once-weekly human GLP-1 analogue semaglutide provides significant reductions in HbA1c and body weight in patients with type 2 diabetes

被引：0
|
作者：
Nauck, M. A. [1 ]
Petrie, J. R. [2 ]
Sesti, G. [3 ]
Mannucci, E. [4 ]
Courreges, J-P [5 ]
Atkin, S. [6 ]
Duering, M. [7 ]
Jensen, C. B. [7 ]
Heller, S. [8 ]
机构：
[1] Ctr Diabet, Bad Lauterberg Im Harz, Germany
[2] Univ Glasgow, Glasgow G12 8QQ, Lanark, Scotland
[3] Magna Graecia Univ Catanzaro, Catanzaro, Italy
[4] Careggi Teaching Hosp, Florence, Italy
[5] Gen Hosp, Narbonne, France
[6] Hull York Med Sch, Kingston Upon Hull, N Humberside, England
[7] Novo Nordisk, Soborg, Denmark
[8] Univ Sheffield, Sheffield S10 2TN, S Yorkshire, England
来源：
DIABETOLOGIA | 2012年 / 55卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2
引用
收藏
页码：S7 / S7
页数：1
相关论文
共 50 条
  • [31] COST-UTILITY ANALYSIS OF ONCE-WEEKLY SEMAGLUTIDE VERSUS DULAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES REQUIRING TREATMENT WITH A GLP-1 RECEPTOR AGONIST
    Uranga, Garcia J.
    Jung, S.
    Dahaoui, Smeat
    VALUE IN HEALTH, 2022, 25 (12) : S160 - S160
  • [32] Semaglutide Once-Weekly Persistence and Adherence Versus Other GLP-1 RAs in Patients with Type 2 Diabetes in a US Real-World Setting
    Uzoigwe, Chioma
    Liang, Yuanjie
    Whitmire, Sarah
    Paprocki, Yurek
    DIABETES THERAPY, 2021, 12 (05) : 1475 - 1489
  • [33] Retatrutide, a triple GIP/GLP-1/glucagon receptor agonist, provides robust HbA1c and body weight reductions to people with type 2 diabetes: a 36-week, phase 2 study
    Coskun, T.
    Rosenstock, J.
    Frias, J.
    Jastreboff, A.
    Du, Y.
    Lou, J.
    Gurbuz, S.
    Hartman, M. L.
    Haupt, A.
    Milicevic, Z.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S31 - S31
  • [34] Effect of once-weekly semaglutide 2 mg vs 1 mg on HbA1c and body weight by baseline demographic subgroups: SUSTAIN FORTE post hoc analysis
    Frias, J. P.
    Bardtrum, L.
    Hansen, Y.
    Lingvay, I.
    Macura, S.
    Tentolouris, N.
    Buse, J. B.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S289 - S290
  • [35] Reductions in HbA1c and body weight with 2 years of exenatide treatment in overweight patients with type 2 diabetes
    Ivanyi, Tibor
    Guan, Xuesong
    Mac, Susanna
    Holcombe, John
    Blonde, Lawrence
    INTERNATIONAL JOURNAL OF OBESITY, 2007, 31 : S27 - S27
  • [36] GREATER COMBINED REDUCTIONS IN HbA1C ≥1.0% AND WEIGHT ≥5.0% WITH SEMAGLUTIDE VERSUS COMPARATORS IN TYPE 2 DIABETES
    Rodbard, Helena W.
    Bellary, Srikanth
    Hramiak, Irene
    Seino, Yutaka
    Silver, Robert
    Damgaard, Lars Holm
    Nayak, Gurudutt
    Zacho, Jeppe
    Aroda, Vanita R.
    ENDOCRINE PRACTICE, 2019, 25 (06) : 589 - 597
  • [37] In type 2 diabetes, weekly semaglutide reduced HbA1c and increased weight loss more than weekly ER exenatide
    Bekiari, Eleni
    Karagiannis, Thomas
    Tsapas, Apostolos
    ANNALS OF INTERNAL MEDICINE, 2018, 168 (08) : JC46 - JC46
  • [38] Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes
    Goldman, Jennifer D.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2020, 45 : 61 - 72
  • [39] The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 Diabetes: a systematic literature review
    Ruan, Zhen
    Yang, Lisong
    Shi, Honghao
    Yue, Xiaomeng
    Wang, Yao
    Liang, Miaoying
    Hu, Hao
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (02) : 221 - 233
  • [40] Effectiveness and Tolerability of Once-Weekly GLP-1 Receptor Agonists in Clinical Practice: A Focus on Switching Between Once-Weekly Molecules in Type 2 Diabetes
    Di Dalmazi, Giulia
    Coluzzi, Sara
    Baldassarre, Maria Pompea Antonia
    Ghit, Amr
    Graziano, Giusi
    Rossi, Maria Chiara
    Ciappini, Beatrice
    Milo, Marica
    Carrieri, Federica
    Nicolucci, Antonio
    Consoli, Agostino
    Formoso, Gloria
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
12345